Last updated: July 29, 2025
Introduction
European Patent EP4134101, titled “Method for treating or preventing cancer using a combination of an anti-PD-1 antibody and a TGF-β inhibitor,” exemplifies innovation at the intersection of immunotherapy and targeted cancer treatments. This patent landscape analysis delineates the scope of the claims, explores the contextual patent environment, and assesses strategic considerations for stakeholders. Such an examination aids pharmaceutical developers, patent strategists, and R&D entities in understanding both the protection conferred by EP4134101 and its positioning within the broader oncology patent landscape.
Scope and Claims of EP4134101
Claim Focus and Claims Construction
The core invention centers around a combination therapeutic comprising an anti-PD-1 monoclonal antibody and a transforming growth factor-beta (TGF-β) pathway inhibitor, particularly for the treatment or prevention of cancers. The claims are structured to encompass various embodiments of this combination, including methods, compositions, and uses, with a notable emphasis on:
- Methods of administration involving simultaneous or sequential application of the two agents.
- Specific dosages, dosing regimens, and formulations tailored to optimize therapeutic efficacy.
- Types of TGF-β inhibitors, which range from small molecules to biologics, including but not limited to monoclonal antibodies and ligand traps.
- Targeted indications such as solid tumors, metastatic cancers, and specific subtypes like non-small-cell lung cancer (NSCLC).
Key Claim Elements
The claims delineate several critical aspects:
- Combination efficacy: The patent explicitly claims the synergistic effect of combining anti-PD-1 antibodies with TGF-β inhibitors, supported by experimental data.
- Broadened scope: Claims extend to different anti-PD-1 antibodies (e.g., nivolumab, pembrolizumab) and various TGF-β inhibitors, enhancing the patent’s territorial and functional coverage.
- Method of use: Emphasis on treating refractory or resistant tumors, especially in cases where monotherapies have limited efficacy, aligning with current trends toward combination immunotherapy.
Claim Limitations and Exclusions
While comprehensive, the claims explicitly exclude monotherapies, focusing solely on the combination modality. Moreover, certain claims specify preferred sequences or timing of drug administration to optimize synergy.
Patent Landscape Overview
1. Existing Patents on Anti-PD-1 and TGF-β Inhibition
The patent landscape surrounding this invention comprises several prior and emerging patents:
- Anti-PD-1 antibodies: Patent families covering nivolumab (e.g., US Patent 7,943,982) and pembrolizumab (e.g., US Patent 8,197,434). These dominate the anti-PD-1 space and are already heavily patented.
- TGF-β inhibitors: Broad patent coverage around small molecules (e.g., galunisertib - LY2157299), ligand traps (e.g., AVID200), and monoclonal antibodies targeting TGF-β isoforms (e.g., Fresenius' Fresolimumab).
2. Combination Therapies Targeting Both Pathways
Patents combining immune checkpoint inhibition with TGF-β modulation are emerging. For instance:
- US Patent 10,938,094 claims combinations of TGF-β inhibitors with anti-PD-L1 antibodies.
- Patent families from AstraZeneca and Merck also explore dual-targeted antibody constructs and combination regimens.
3. Novelty and Non-Obviousness
EP4134101’s claims are underpinned by data demonstrating synergistic efficacy. Its novelty is reinforced by the specific combination, indication scope, and dosing regimens, which distinguish it from prior art involving monotherapies or unrelated combinations.
Strategic Implications
1. Competitive Positioning
EP4134101 solidifies a strategic patent position for combination immunotherapy, potentially covering a broad swath of clinical applications. Its claims may intersect existing patents but notably carve out innovation specific to the combination paradigm.
2. Freedom-to-Operate Considerations
Given extensive prior art on both anti-PD-1 and TGF-β inhibitors, practitioners should scrutinize overlapping patent claims, especially regarding specific antibody sequences and inhibitor classes. The breadth of the claims necessitates careful clearance analyses for specific combination partners.
3. Licensing and Infringement Risks
Companies involved in developing combined therapies involving TGF-β inhibitors and anti-PD-1 agents should explore licensing opportunities or design around the claims—such as alternative dosing schedules, novel inhibitors, or delivery methods.
Legal and Patentability Aspects
- Scope of protection: The patent’s durability hinges on its claims’ breadth and the novelty of the specific combination therapy.
- Potential challenges: Art-based invalidation could target any prior disclosures of similar combinations, especially if certain claims lack novelty or are obvious to experts.
- Maintaining patent life: Given the rapidly evolving oncology patent landscape, ongoing patent filings covering next-generation inhibitors and novel formulations are critical.
Conclusion
European Patent EP4134101 marks a significant advancement in combination immunotherapy for cancer, offering broad protective claims around anti-PD-1 antibodies combined with TGF-β pathway inhibitors. Its scope encompasses various agents, methods, and indications, reinforcing its strategic value. However, the densely populated patent landscape underscores the necessity for detailed freedom-to-operate analyses, inventive step verification, and potential licensing negotiations to leverage this patent effectively.
Key Takeaways
- EP4134101’s claims primarily protect a method of combining anti-PD-1 antibodies with TGF-β inhibitors, emphasizing synergistic anti-cancer effects.
- The patent landscape is crowded, with existing patents covering individual agents and some combination therapies; therefore, strategic positioning and clearance analyses are vital.
- Broad claims cover various formulations, dosing regimens, and indications, which could provide a competitive edge but also risk infringement challenges.
- Innovation in dosing schedules, novel inhibitors, or delivery methods may be essential for differentiation and avoiding patent infringement.
- This patent reinforces the commercial value of combination immunotherapy approaches in oncology, aligning with current clinical and R&D trends.
FAQs
1. How does EP4134101 differ from existing patents on anti-PD-1 or TGF-β inhibitors?
It specifically claims the combined therapeutic method involving both agents, supported by data showing synergistic effects, unlike existing patents which typically cover monotherapies or individual agents.
2. Can this patent be challenged or licensed?
Yes, due to the complex patent landscape, it’s advisable to conduct freedom-to-operate assessments. Licensing negotiations can also be explored to mitigate infringement risks.
3. Does the patent specify particular TGF-β inhibitors or is it broad?
The claims are broad, encompassing various classes including monoclonal antibodies, small molecules, and ligand traps.
4. What cancer types are covered by this patent?
Primarily solid tumors and advanced/metastatic cancers, including non-small cell lung cancer (NSCLC), but the claims are designed to be applicable across multiple indications.
5. How long is the patent protection likely to last?
Assuming maintenance fees are paid, patent protection in Europe generally extends 20 years from the filing date.
References
[1] European Patent Office, EP4134101 publication details.
[2] Patent landscape reports on anti-PD-1 (e.g., nivolumab, pembrolizumab) patents.
[3] Literature on TGF-β inhibitors and combination immunotherapies.
[4] Prior art references including US patents and scientific publications on combination cancer therapies.
